UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant x | |||
| |||
Filed by a Party other than the Registrant o | |||
| |||
Check the appropriate box: | |||
o | Preliminary Proxy Statement | ||
o | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | ||
o | Definitive Proxy Statement | ||
x | Definitive Additional Materials | ||
o | Soliciting Material under §240.14a-12 | ||
| |||
Cardiff Oncology, Inc. | |||
|
|
|
|
(Name of Registrant as Specified In Its Charter) | |||
| |||
| |||
(Name of Person(s) Filing Proxy Statement, if other than the Registrant) | |||
| |||
Payment of Filing Fee (Check the appropriate box): | |||
x | No fee required. | ||
|
|
| |
o | Fee paid previously with preliminary materials. | ||
|
|
|
|
o | Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11 | ||
NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS
The Annual Meeting of Stockholders of Cardiff Oncology, Inc. will be held on June 11, 2026, at 8:00 a.m. local time at the Company’s offices located at 11055 Flintkote Avenue, San Diego, California 92121
PROXY STATEMENT AND 2025 ANNUAL REPORT ON FORM 10-K ARE AVAILABLE AT:
https://annualgeneralmeetings.com/crdf2026
Dear Stockholder:
The Annual Meeting of Stockholders of Cardiff Oncology, Inc. has been called to consider and act upon the following
matters:
Proposal 1: Election of six (6) Directors;
Proposal 2: Ratification of BDO USA, P.C. as Cardiff Oncology’s independent registered public accountants for fiscal year ending December 31, 2026;
Proposal 3: Approve an amendment to the Company’s 2021 Omnibus Equity Incentive Plan to increase the number of shares issuable thereunder to 15,150,000 shares from 12,150,000 shares; and
Proposal 4: Approve, on an advisory basis, the compensation of the Company’s named executive officers.
Our Board of Directors recommends a vote “FOR” all nominees listed in proposal 1 and “FOR” proposals 2, 3 and 4.
You are receiving this communication because you hold shares in the company named above. Complete proxy materials, including the proxy card, are available to you on-line at https://annualgeneralmeetings.com/crdf2026 or upon your request by e-mail or first-class mail. We encourage you to access and review all of the important information contained in the proxy
materials before voting.
This is not a ballot. You cannot use this notice to vote your shares. You may vote on-line, by mail or in person. If you wish to vote on-line, you will need your “Control Number” (which can be found in the bottom right hand corner of this notice) and the web address, all of which will be included with or on the proxy card located on the Internet website stated above or mailed to you at your request. No other personal information will be required in order to vote in this manner. If you wish to vote by mail, simply print out the proxy card located on the Internet website stated above, mark the proxy card accordingly, sign and return it to us at the address indicated on the proxy card. If you wish to vote in person at the Annual Meeting of Stockhold ers, simply check the box on the proxy card that you plan to attend. Your proxy card will not be used if you vote in person. Please check the meeting materials for any special requirements for meeting attendance and how to obtain directions to the meeting.
Control Number:
Important Notice Regarding the Availability of Proxy Materials
for the Stockholder Meeting To Be Held on June 11, 2026:
https://annualgeneralmeetings.com/crdf2026
To request a paper copy of these items:
Please clearly identify the items you are requesting; Cardiff Oncology, Inc., and your name along with the Control Number located in the lower right hand corner of this notice and the name and address to which the materials should be mailed.
By Order of the Board of Directors
/s/ Dr. Rodney S. Markin MD, Ph.D. Chairman of the Board of Directors
Control Number:
